Clevudine: meta-analysis of COVID-19 studies

All studies Recovery Viral clearance RCTs All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−744%

Viral clearance (1)27%

RCTs (1)−744%

Late (1)−744%

00.511.5+

← Clevudine
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

Clevudine COVID-19 studies (1 unreported RCT)

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Song (SB RCT)−744%8.44 · 0.49–146no recov.5/410/20BK-CLV-201 Song (DB RCT)n/a< NOT REPORTED >104 (total)>5 years late

Late treatment−744%8.44 · 0.49–1465/410/20744% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.14

All studies−744%8.44 · 0.49–1465/410/20744% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1400.511.52+

Rotate screen for more detailsIncrease width for more details

← Clevudine
reduces riskClevudine
increases risk →

October 2026

Clevudine COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Song (SB RCT)−744%8.44 · 0.49–146no recov.5/410/20BK-CLV-201

Late treatment−744%8.44 · 0.49–1465/410/20744% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.14

All studies−744%8.44 · 0.49–1465/410/20744% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1400.511.52+

Rotate screen for more detailsIncrease width for more details

← Clevudine
reduces riskClevudine
increases risk →

October 2026

Clevudine COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Song (SB RCT)27%0.73 · 0.36–1.50viral+12/418/20BK-CLV-201

Late treatment27%0.73 · 0.36–1.5012/418/2027% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.4

All studies27%0.73 · 0.36–1.5012/418/2027% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.400.511.52+

Rotate screen for more detailsIncrease width for more details

← Clevudine
reduces riskClevudine
increases risk →

October 2026

Clevudine COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Song (SB RCT)−744%8.44 · 0.49–146no recov.5/410/20BK-CLV-201 Song (DB RCT)n/a< NOT REPORTED >104 (total)>5 years late

Late treatment−744%8.44 · 0.49–1465/410/20744% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.14

All studies−744%8.44 · 0.49–1465/410/20744% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1400.511.52+

Rotate screen for more detailsIncrease width for more details

← Clevudine
reduces riskClevudine
increases risk →

October 2026

Clevudine COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Song (SB RCT)−744%8.44 · 0.49–146no recov.5/410/20BK-CLV-201 Song (SB RCT)27%0.73 · 0.36–1.50viral+12/418/20BK-CLV-201 Song (SB RCT)−22%1.22 · 0.65–2.27viral+20/418/20BK-CLV-201 Song (SB RCT)6%0.94 · 0.68–1.30viral+29/4115/20BK-CLV-201 Song (SB RCT)5%0.95 · 0.78–1.15viral+35/4118/20BK-CLV-201

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Clevudine
reduces riskClevudine
increases risk →